The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapy

INTRODUCTION: The ability to modulate and enhance the anti-tumor immune responses is critical in developing novel therapies in cancer. The Tumor Necrosis Factor (TNF) Receptor Super Family (TNFRSF) are potentially excellent targets for modulation which result in specific anti-tumor immune responses....

Descripción completa

Detalles Bibliográficos
Autores principales: Frankish, Jamie, Mukherjee, Debayan, Romano, Erminia, Billian-Frey, Katharina, Schröder, Matthias, Heinonen, Karl, Merz, Christian, Redondo Müller, Mauricio, Gieffers, Christian, Hill, Oliver, Thiemann, Meinolf, Honeychurch, Jamie, Illidge, Tim, Sykora, Jaromir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251205/
https://www.ncbi.nlm.nih.gov/pubmed/37304285
http://dx.doi.org/10.3389/fimmu.2023.1160116

Ejemplares similares

Ejemplares similares